This Week in Science – GenomeWeb
|
This Week in Science
GenomeWeb Also in Science, researchers from MIT’s Synthetic Biology Center discuss the potential of gene programming and genetically engineered cellular therapy, as well as the limitations facing their clinical implementation. Despite some success in treating … |
Seeking Alpha |
Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?
Seeking Alpha The aforementioned statement suggested that there’s a favorable chance that Gilead is sizing up the following leading gene editing innovators for acquisition: CRISPR Therapeutics (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics … |
|
BMS Immunotherapy Combo Study Backs FoundationOne CDx Tumor Mutational Burden Indication
GenomeWeb NEW YORK (GenomeWeb) – A study evaluating the combination of Bristol-Myers Squibb’s immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) may support regulatory approval for the regimen as an option for lung cancer patients with a large number of … Phase 3 CheckMate-227 Trial Met Co-Primary Endpoint of PFS in NSCLCAJMC.com Managed Markets Network |